Cryoport, Inc. filings document the regulatory record for a Nasdaq-listed Nevada corporation providing temperature-controlled supply chain solutions to life sciences customers. Recent Form 8-K reports furnish quarterly and annual results releases, while definitive proxy materials describe governance matters, stockholder voting items and business updates tied to Life Sciences Services and Life Sciences Products.
The filing record also identifies Cryoport's registered common stock and recurring disclosure subjects such as operating performance, commercial and clinical cell and gene therapy support, biostorage and bioservices activity, cryogenic systems demand, executive and board governance, and stockholder meeting materials.
Cryoport, Inc. Chief Financial Officer Robert Stefanovich reported an open-market sale of 169,427 shares of Cryoport common stock. The sale occurred on June 4, 2026 at a weighted average price of $16.2724 per share, with individual sale prices ranging from $16.05 to $16.70. Following this transaction, Stefanovich directly owns 109,850 Cryoport common shares.
Cryoport, Inc. director Daniel M. Hancock reported equity awards consisting of restricted stock and stock options. He received 10,350 restricted stock rights that vest in full on June 5, 2027 and will convert into the same number of common shares when vested.
He was also granted options to buy 16,077 shares of common stock at an exercise price of $15.70 per share, expiring on June 5, 2033. One-twelfth of these options vest monthly on the 5th, starting July 5, 2026. Following the grants, he directly holds 69,052 common shares.
Cryoport, Inc. director Robert J. Hariri reported equity compensation awards. He received 10,350 restricted stock rights that vest in full on June 5, 2027 and then convert one-for-one into common shares.
He was also granted options for 16,077 shares of common stock at an exercise price of $15.70 per share, expiring on June 5, 2033, with 1/12 of the options vesting monthly beginning July 5, 2026. Following these awards, he directly holds 61,625 shares of common stock, plus the new option grant.
Cryoport, Inc. director Ramkumar Mandalam reported a mix of equity grants and a stock sale. On June 5, 2026, he received 10,350 restricted stock rights that vest in full on June 5, 2027 and convert one-for-one into common shares, plus options for 16,077 shares at an exercise price of $15.70 expiring in 2033.
On June 8, 2026, he executed an open-market sale of 23,214 common shares at a weighted average price of $15.4412 per share, in multiple trades between $15.40 and $15.48. Following the sale, he directly holds 67,894 common shares.
Cryoport, Inc. director Ramkumar Mandalam reported a proposed sale of 23,214 common shares, with an aggregate market value of $358,452.02 and an approximate sale date of June 8, 2026. The shares were acquired on June 6, 2026 through restricted stock vesting under a registered plan.
Cryoport, Inc. officer Robert Stefanovich reported a proposed sale of 169,427 common shares, with an approximate sale date of June 4, 2026 and an aggregate market value of $2,795,545.50. Edward Jones is listed as the broker.
Cryoport, Inc. reports Q1 2026 results with total revenue of $47.8 million, up from $41.0 million a year earlier, driven by both services and products. Life Sciences Services contributed $26.9 million and Life Sciences Products $20.9 million.
The company recorded a loss from operations of $9.6 million versus $7.2 million last year, and a net loss of $10.5 million compared with $12.0 million. Net loss attributable to common stockholders was $12.5 million, or $0.25 per share, including a $2.0 million paid‑in‑kind dividend on Series C preferred stock.
Cryoport classified its former CRYOPDP courier business as discontinued operations following its 2025 divestiture and booked a $1.1 million loss from discontinued operations tied to an adjustment on the disposal. The company ended the quarter with $403.6 million in cash, cash equivalents and short‑term investments and generated $3.7 million of operating cash flow, while carrying $186.2 million of 0.75% Convertible Senior Notes due in 2026.
Cryoport, Inc. reported a strong start to 2026, with first-quarter revenue of $47.8 million, up 16% year-over-year. Life Sciences Services revenue rose to $26.9 million (up 18%), and Life Sciences Products reached $20.9 million (up 15%), driven by demand for cryogenic systems and integrated logistics.
Revenue supporting commercial cell and gene therapies grew 26% to $9.1 million, while clinical trial support revenue increased 18% to $12.9 million. The company supported 766 clinical trials as of March 31, 2026, including 91 in Phase 3 and 21 commercial therapies.
Despite growth, Cryoport posted a loss from continuing operations of $9.4 million and a net loss of $10.5 million, or -$0.25 per share, though adjusted EBITDA from continuing operations improved to -$0.6 million from -$2.8 million. Cash and cash equivalents were $272.9 million with $130.7 million in short-term investments, and full-year 2026 revenue guidance was raised to $192–$196 million.
Cryoport, Inc. President and CEO Jerrell Shelton exercised stock options to acquire 104,007 shares of common stock at $1.87 per share. These options, which vested monthly over four years beginning May 6, 2016, were fully exercised, leaving 0 options from this grant. After the transaction, Shelton directly holds 1,230,614 common shares, indicating an exercise-and-hold pattern with no same-day share sales reported.